The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.
Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.
Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.
Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.
Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.
The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.
A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.
Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.
Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.
Patients who presented with an MRD level below 10-6 had a significantly improved PFS compared with patients who were above this threshold.
Researchers analyzed the outcomes of 67 patients with BCR-ABL1-positive CML in chronic phase who had an MMR on nilotinib twice daily and who then switched to a once-daily reduced-dose regimen.
Ninety-five percent of patients received elotuzumab at the increased rate of 5 mL/min without any incidence of IR.
Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.
Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.
Based on findings from previous studies (COG AALL0031 and EsPhALL 2004-2009), researchers are assessing the association of continuous imatinib plus chemotherapy with the reduced need for HSCT.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Axillary Node Management for Breast Cancer: Is Less More?
- Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer
- Potentially Inappropriate Medications May Shorten Survival Among Elderly Patients With Lymphoma
- Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma
- The Potential of Radium-223 in Modern Prostate Cancer Treatment
- Colorectal Cancer Screening: Utility of Septin-9 Assays
- Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC
- Phase 2 Study of Nivolumab Plus Ipilimumab for Gastric, Ovarian, and Breast Cancer
- Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
- Priming Lung Cancer To Respond to Immunotherapy: Findings and Current Research